Adial Pharmaceuticals is preparing to advance AT177 into the clinic in 2027, targeting an Investigational New Drug application during the first half of the year followed by the start of a Phase 1a clinical trial during the second half.
The development timeline has become the central near-term focus for Adial following its acquisition of Azora Therapeutics, which brought AT177 into the pipeline and shifted the company’s strategy toward inflammatory diseases.
AT177 is currently undergoing IND-enabling studies as Adial works through the preclinical and chemistry, manufacturing and controls activities required to support the planned regulatory filing.
If the IND proceeds on schedule, Adial expects to initiate a Phase 1a single- and multiple-ascending-dose study during the second half of 2027.
The study would represent the first clinical evaluation of AT177 and provide initial information about the drug’s safety, tolerability and pharmacologic profile.
Adial then plans to advance the program into a Phase 1b proof-of-concept study in patients with ulcerative colitis.
That sequencing would allow the company to first establish a clinical foundation in healthy participants or an early-stage study population before evaluating AT177 more directly in patients with the disease it is being developed to treat.
AT177 is a fully synthetic, oral and colon-targeted aryl hydrocarbon receptor agonist.
The candidate is designed as a prodrug that releases its active AhR agonist specifically in the colon.
Adial believes that approach could allow AT177 to concentrate therapeutic activity at the primary site of ulcerative colitis while reducing systemic exposure.
The company sees that localized delivery profile as a potential point of differentiation from earlier AhR agonists.
AhR signaling has been clinically validated as a pathway capable of influencing immune homeostasis and epithelial barrier function, two biological processes relevant to ulcerative colitis.
Adial’s strategy is to pair that mechanism with targeted delivery to the colon in an effort to capture the therapeutic benefits of AhR activation without requiring high systemic drug exposure.
The company’s ability to pursue the 2027 clinical timeline was strengthened considerably by financing completed alongside the Azora acquisition.
Adial closed the first $32 million tranche of a private placement that could ultimately provide up to $64 million.
The initial tranche included the conversion of approximately $5.5 million of notes and was led by biotechnology-focused institutional investors.
Cash and cash equivalents increased from $4.6 million at March 31, 2026, to $28.7 million at June 30.
Management believes the current cash position is sufficient to fund operations into the second half of 2027.
Importantly, that runway estimate does not assume receipt of the second $32 million milestone-based financing tranche.
That means Adial currently expects to have enough capital to progress through several of the most important AT177 milestones, including IND-enabling work, the planned first-half 2027 filing and the targeted Phase 1a launch during the second half of the year, without depending on the additional financing.
If the second tranche is received, it could provide further financial flexibility beyond the company’s existing runway.
The combination of the Azora acquisition and financing has substantially changed Adial’s operating and development profile.
The company historically focused on therapies for addiction and related disorders.
Following the June 2026 acquisition of Azora, Adial shifted its primary strategic focus toward serious inflammatory diseases, with AT177 becoming the lead development program.
The transaction therefore transformed both the company’s pipeline and the milestones investors will be watching over the next year.
Adial’s immediate execution priorities now center on completing AT177’s preclinical work, advancing CMC activities and assembling the regulatory package needed for the planned IND filing.
Successfully reaching the IND milestone in the first half of 2027 would position the company to begin human testing later that year.
The Phase 1a start would then mark a further transition for AT177 from a preclinical asset into a clinical-stage program.
Financial results for the second quarter reflected the impact of that strategic transition.
Adial reported a net loss of $52 million compared with $2 million during the prior-year period.
The majority of that increase came from a $46.2 million non-cash acquired in-process research and development charge related to the Azora acquisition.
The charge represented the fair value of acquired research and development with no alternative future use and did not affect Adial’s cash position or stated operating runway.
General and administrative expenses increased to $5.4 million from $1.2 million, primarily because of merger-related expenses and severance costs.
Research and development expenses declined to $440,000 from $732,000 as activity slowed while the company was engaged in merger discussions.
Those quarterly accounting effects are secondary to the development milestones now shaping Adial’s outlook.
The company enters the remainder of 2026 with AT177 in IND-enabling development, approximately $28.7 million in cash at quarter-end and a stated runway extending into the second half of 2027.
That timetable gives Adial a defined sequence of potential catalysts.
The first is completion of the remaining preclinical and CMC work required to support the regulatory submission.
The next is the targeted IND filing during the first half of 2027.
The company then plans to initiate the Phase 1a single- and multiple-ascending-dose trial during the second half of 2027, followed eventually by the Phase 1b proof-of-concept study in ulcerative colitis patients.
With its financing completed and strategic focus reset around inflammatory disease, Adial’s near-term story is increasingly centered on whether it can execute that timeline and move AT177 from IND-enabling development into human testing during 2027.
KEY QUOTES:
“The acquisition of Azora Therapeutics and the concurrent financing mark an important inflection point for Adial. AT177 establishes a new strategic focus for the Company around a differentiated approach to treating ulcerative colitis, an area where many patients continue to experience inadequate outcomes despite a growing number of therapies.”
“AT177 is built on a mechanism with demonstrated clinical benefit, delivered in a form designed to concentrate activity in the colon, where it matters. Our focus is now on advancing AT177 into the clinic in 2027 and building long-term value for patients and shareholders.”
Cary Claiborne, Chief Executive Officer of Adial Pharmaceuticals
“AhR signaling is a clinically validated pathway with the potential to restore immune homeostasis and epithelial barrier function in ulcerative colitis. AT177 is differentiated by design, a fully synthetic, oral prodrug engineered to release the active AhR agonist in the colon, where disease occurs, while minimizing systemic exposure.”
“We believe this targeted delivery strategy addresses an important limitation of earlier AhR agonists and positions AT177 to capture the promise of localized AhR activation with a potentially better safety profile. With strong progress across our preclinical and CMC programs, we remain on track to file an IND in the first half of 2027.”
Matt Davidson, Ph.D., Chief Development Officer and Director of Adial Pharmaceuticals
